BioSpace News Archive

Abcam today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx).

Funding to advance novel drug for acute, painful muscle spasms and spasticity without sedation

Amneal (NYSE: AMRX), a specialty pharmaceutical company, today announced it has initiated a Phase 3 trial for IPX203.

Conference call scheduled for Tuesday May 8th at 9am EDT to discuss the impact of this major transformative event

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) for cash consideration of $2.3 million.

Neurotrope, Inc. is announcing that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, has completed the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer’s disease.

Selexis SA today announced that the Swiss Biotech Association (SBA) has named Selexis to an esteemed group of five Swiss Biotech Success Stories, as determined by a jury of industry experts, based upon the company’s contributions to the biotechnology industry in Switzerland.

Presentation will be Webcast Live and Archived on Vanda’s Website

Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies

athenahealth, Inc. (NASDAQ: ATHN), a leading provider of network-enabled services for hospital and ambulatory customers nationwide, today confirmed that it has received an unsolicited proposal from Elliott Management to acquire the Company for $160 per share in cash.